Subclinical Atherosclerosis in the 2026 Multisociety Cholesterol Guidelines
In the context of the 2026 multisociety cholesterol guidelines, subclinical atherosclerosis refers to the presence of atherosclerotic plaque detected by imaging (such as coronary artery calcium scoring, CT angiography, or carotid ultrasound) in asymptomatic individuals who have never experienced a clinical cardiovascular event.
Core Definition
Subclinical atherosclerosis represents the structural presence of atherosclerotic disease without clinical symptoms or ischemic events 1, 2. This is fundamentally different from clinical atherosclerosis, where patients have experienced symptomatic manifestations such as myocardial infarction, stroke, or chronic limb-threatening ischemia 2.
Key Characteristics
The 2026 guidelines recognize subclinical atherosclerosis through several imaging modalities:
- Coronary artery calcium (CAC) scoring: A CAC score >0 indicates the presence of coronary atherosclerosis 3
- Carotid ultrasound findings: Visible arterial wall plaques or carotid intima-media thickness (CIMT) ≥1.5 mm 4, 5
- Incidental findings on CT imaging: Detection of coronary plaque on chest CT or cardiac CT performed for other indications 6
- Coronary CT angiography: Showing nonobstructive coronary artery disease 7
Clinical Significance and Risk Stratification
The presence of subclinical atherosclerosis fundamentally changes risk assessment and treatment decisions. The 2026 guidelines introduce the concept of "advanced subclinical atherosclerosis" as a distinct clinical category that sits between traditional primary and secondary prevention 8. This is critical because:
- Individuals with CAC >300 or extensive plaque burden may have cardiovascular event rates equal to or exceeding those in certain secondary prevention populations 3, 8
- A CAC score of 0 has a negative predictive value exceeding 98% for ruling out significant coronary atherosclerosis 4
- Patients with 0 risk factors but CAC >300 have event rates 3.5 times higher than those with ≥3 risk factors but CAC of 0 3
Treatment Implications
When subclinical atherosclerosis is detected, patients should be treated more aggressively, often with intensity approaching secondary prevention strategies 1, 6. The guidelines recommend:
- Upgrading risk estimates when CAC ≥300 or ≥75th percentile for age and sex 3
- Considering statin therapy initiation or intensification regardless of calculated risk score 4
- Setting LDL-C treatment goals similar to higher-risk categories 1
Important Caveats
The guidelines acknowledge that not all subclinical atherosclerosis carries the same risk. The extent and composition of plaque matter significantly:
- Calcified plaque indicates atherosclerosis burden but doesn't necessarily indicate plaque instability 9, 10
- The presence of coronary calcium proves "coronary disease" but doesn't necessarily reflect hemodynamically significant stenosis (≥50% narrowing) 9
- Multiple imaging modalities may be needed to fully characterize plaque burden and guide treatment intensity 11, 2
The 2026 guidelines emphasize that detecting subclinical atherosclerosis through imaging provides an opportunity for intensive risk factor modification before clinical events occur, representing a paradigm shift toward plaque-burden-guided rather than purely risk-factor-based prevention 3, 6.